Eledon Pharmaceuticals (ELDN) Equity Average (2016 - 2017)
Historic Equity Average for Eledon Pharmaceuticals (ELDN) over the last 4 years, with Q3 2017 value amounting to $22.0 million.
- Eledon Pharmaceuticals' Equity Average fell 3627.8% to $22.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $22.0 million, marking a year-over-year decrease of 3627.8%. This contributed to the annual value of $29.5 million for FY2016, which is 6427.78% down from last year.
- According to the latest figures from Q3 2017, Eledon Pharmaceuticals' Equity Average is $22.0 million, which was down 3627.8% from $23.4 million recorded in Q2 2017.
- Eledon Pharmaceuticals' 5-year Equity Average high stood at $102.6 million for Q4 2014, and its period low was $10.3 million during Q1 2017.
- For the 4-year period, Eledon Pharmaceuticals' Equity Average averaged around $53.0 million, with its median value being $50.9 million (2016).
- Its Equity Average has fluctuated over the past 5 years, first crashed by 3485.36% in 2015, then plummeted by 8173.62% in 2017.
- Eledon Pharmaceuticals' Equity Average (Quarter) stood at $102.6 million in 2014, then tumbled by 34.85% to $66.8 million in 2015, then crashed by 79.38% to $13.8 million in 2016, then surged by 59.89% to $22.0 million in 2017.
- Its last three reported values are $22.0 million in Q3 2017, $23.4 million for Q2 2017, and $10.3 million during Q1 2017.